Sort   by:  
 Page size 
ProteomicsLFQ proteomics analysis of M. smegmatis treated with BacPROTACs.
To monitor selective degradation of ClpC1 and ClpC2 using BacPROTAC compounds in M. smegmatis we performed a LFQ proteomics analysis treating the cells at bactericidal compound concentration. We detected degradation of both proteins and additional dysregulation of the mycobacterial PQC system.
ORGANISM(S): Mycobacterium smegmatis (strain ATCC 700084 / mc(2)155) 
2023-06-07 | PXD037235 | Pride
Antibiotics Tpd Bacprotac Protac Protein degradation 
ProteomicsLFQ proteomics analysis of the M. smegmatis ClpC2 interactome.
To assess the ClpC2 interactome, a IP-MS analysis was performed using ectopically expressed tagged ClpC2 in a ClpC2 deficient cell line. To evaluate potential binding sites on ClpC2, CymA treatment was applied to compete with potential interactors for a shared ClpC2 binding site.
ORGANISM(S): Mycobacterium smegmatis (strain ATCC 700084 / mc(2)155) 
2023-06-07 | PXD037231 | Pride
Antibiotics Tpd Protein degradation 
ProteomicsA quantitative proteomics approach to monitor targeted protein degradation in M. smegmatis
Targeted protein degradation via the ubiquitin proteasome has been established in eukaryotes, however no application has been shown in bacteria so far. In the present work, selective protein degradation is shown using hetero bifunctional drugs, bringing substrates in close proximity to the bacterial...
ORGANISM(S): Mycobacterium smegmatis (strain ATCC 700084 / mc(2)155) Bacteria 
2022-08-12 | PXD021505 | Pride
Mycobacteria Targeted protein degradation Protease Tpd 
ProteomicsLFQ proteomics analysis of M. smegmatis treated with CymA and ecumicin (Part 1).
To assess the impact of the bactericidal compounds CymA and ecumicin on the mycobacterial proteome and to monitor proteome remodeling by the AAA+ ClpC1 protease machinery, we performed a LFQ proteomics analysis treating the cells at sub-bactericidal compound concentration. We identified new players ...
ORGANISM(S): Mycobacterium smegmatis (strain ATCC 700084 / mc(2)155) 
2023-06-07 | PXD037232 | Pride
Tuberculosis Tpd Protein degradation 
ProteomicsLFQ proteomics analysis of M. smegmatis treated with CymA and ecumicin (Part 2).
To assess the impact of the bactericidal compounds CymA and ecumicin on the mycobacterial proteome and to monitor proteome remodeling by the AAA+ ClpC1 protease machinery, we performed a LFQ proteomics analysis treating the cells at bactericidal compound concentration. We identified new players of t...
ORGANISM(S): Mycobacterium smegmatis (strain ATCC 700084 / mc(2)155) 
2023-06-07 | PXD037234 | Pride
Antibiotics Tuberculosis Tpd Protein degradation 
ProteomicsAnalysis of the effect of ClpC1 directed antibiotics on ClpC1, ClpC2 and ClpC3 protein levels.
Ecumicin and Cyclomarin A (CymA) are known antimicrobial compounds that target the NTD of ClpC1. In proteomics analysis of compound treated M. smegmatis, two novel protein, ClpC2 and ClpC3, have been identified as strong interactors of those compounds in addition to ClpC1. In this study we used PRM ...
ORGANISM(S): Mycolicibacterium Smegmatis 
2023-06-07 | PXD037198 | panorama
UnknownSARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808 | biostudies-literature
UnknownExtended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study.
Not available
S-EPMC11894929 | biostudies-literature
UnknownTiming of surgery following SARS-CoV-2 infection: an international prospective cohort study.
Not available
S-EPMC8206995 | biostudies-literature
UnknownSARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
Not available
S-EPMC8652887 | biostudies-literature
Sort   by:  
 Page size